Related Experiment Video
Updated: Jun 21, 2026
06:28
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
Liver function under interferon/ribavirin therapy of chronic hepatitis C
S Stintzing1, C Schmitt, M Ocker
1Department of Medicine 1, University of Erlangen-Nuremberg, Germany.
Hepato-Gastroenterology
|July 8, 2009
Summary
Antiviral therapy for Hepatitis C improved liver function, with most tests normalizing within 3 months. Liver plasma flow parameters normalized after one year, indicating tissue healing. This study monitored liver function during Hepatitis C treatment.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Quantitative testing of liver function (QTLF) is crucial for assessing antiviral treatment efficacy in Hepatitis C.
- Limited data exists on liver function changes during Hepatitis C antiviral therapy.
- This study investigated the impact of antiviral therapy on QTLF in chronic Hepatitis C patients.
Purpose of the Study:
- To evaluate the influence of antiviral therapy on various quantitative measures of liver function.
- To determine the time course of liver function recovery after successful Hepatitis C virus eradication.
Main Methods:
- 107 patients with chronic Hepatitis C (genotype 1) received pegylated-interferon alfa-2a/ribavirin for 48 weeks.
- Quantitative liver function tests (aminopyrine breath test, galactose elimination capacity, sorbitol clearance, indocyanine green clearance) were performed pre-therapy, at 12 weeks, 48 weeks, and 6 months post-therapy.
- Hepatitis C virus RNA (HCV-RNA) and transaminase levels were monitored.
Main Results:
- In therapy responders (97 patients), aminopyrine breath test and galactose elimination capacity normalized within 3 months.
- Liver plasma flow parameters (sorbitol clearance, indocyanine green clearance) normalized after one year of treatment.
- Non-responders showed no change in QTLF; relapsers experienced deterioration after therapy cessation.
Conclusions:
- Successful Hepatitis C virus eradication leads to normalization of all liver function tests within one year.
- Liver plasma flow parameters require longer recovery, likely due to tissue remodeling.
- Antiviral therapy effectively restores liver function in responders.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...